Research programme: malaria therapeutics - Mycosynthetix
Latest Information Update: 30 Jun 2016
At a glance
- Originator Mycosynthetix Inc
- Developer Magellan BioScience Group; Mycosynthetix Inc; University of Hong Kong; University of South Florida
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Malaria
Most Recent Events
- 30 Jun 2016 Early research in Malaria in USA (unspecified route)